Imricor Medical Systems (ASX:IMR) signed a license agreement with Swiss software company Adis SA to commercialize artificial intelligence (AI) modules integrated within its NorthStar 3D mapping system, according to a Thursday filing with the Australian bourse.
The company will provide NorthStar AI modules as software license options, sharing upfront and ongoing revenue with ADIS under the deal, the filing said.
NorthStar and AI modules are undergoing regulatory processes for commercial sale, with plans for launch in Europe, the US, and the Middle East in 2025.
The first module the companies are targeting is one for providing automatic heart segmentation capabilities to NorthStar, which is expected to save time during interventional cardiovascular magnetic resonance procedures by creating 3D anatomical shells of heart chambers from standard MRI images, according to the filing.
Financial terms of the deal were not disclosed.
Imricor Medical Systems shares rose almost 15% in morning trade Thursday and earlier hit their highest since November 2021.
Price (AUD): $1.23, Change: $+0.16, Percent Change: +14.95%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。